W. Tanaka

发表

Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects

W. Zeng, G. Herman, A. Bergman, 2006, Journal of clinical pharmacology.

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double‐blind, placebo‐controlled studies with single oral doses

W. Zeng, G. Herman, A. Bergman, 2005, Clinical pharmacology and therapeutics.

Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury.

Frank D Sistare, Warren E Glaab, L. Lim, 2009, Clinical chemistry.

Plasma MicroRNAs as Diagnostically Sensitive and Specific Biomarkers of Tissue Injury

L. Lim, P. Garrett-engele, Jason M. Johnson, 2009 .

Nonspecific binding of Aβ42 to polypropylene tubes and the effect of Tween-20.

O. Laterza, Wesley K. Tanaka, A. Dallob, 2010, Clinica chimica acta; international journal of clinical chemistry.

A Dual PPAR α/γ Agonist Increases Adiponectin and Improves Plasma Lipid Profiles in Healthy Subjects

Haiyuan Zhu, K. Decochez, B. Keymeulen, 2006 .

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

J. Holst, W. Zeng, C. Deacon, 2006, The Journal of clinical endocrinology and metabolism.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

W. Zeng, G. Herman, A. Bergman, 2006, Clinical therapeutics.

A Phase I Trial of the Dual Farnesyltransferase and Geranylgeranyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Pancreatic Cancer

E. Rosato, J. Tepper, P. Deutsch, 2004, Clinical Cancer Research.

A high-precision fluorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3456-well assay technology.

Gregory T O'Donnell, M. Ferrer, B. Strulovici, 2007, Analytical biochemistry.

Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults.

S. Heymsfield, D. Macneil, Haiyuan Zhu, 2007, The Journal of clinical endocrinology and metabolism.

Quantitative measurement of cysteinyl leukotrienes and leukotriene B₄ in human sputum using ultra high pressure liquid chromatography-tandem mass spectrometry.

O. Laterza, T. Varnell, Wesley K. Tanaka, 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin

H. Greenberg, K. Gottesdiener, A. Mehta, 2015, Clinical pharmacology in drug development.

Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist.

T. Reiss, L. Hendeles, E. Bronsky, 1997, Thorax.

High-throughput simultaneous analysis of RNA, protein, and lipid biomarkers in heterogeneous tissue samples.

Jason J. Z. Liao, M. Marton, Peggy H. Wong, 2011, Clinical chemistry.

Comparison of the effects of new specific azasteroid inhibitors of steroid 5α‐reductase on canine hyperplastic prostate: Suppression of prostatic DHT correlated with prostate regression

S. Cohen, S. Prahalada, T. Nett, 1995, The Prostate.

Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.

S. Waldman, T. Bradstreet, T. Bjornsson, 1995, Hypertension.